Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 4Completed 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 5Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasms 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × fludrocortisone acetate × 1 year × Clear all
NCT06136650 2026-06-03

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
250 enrolled
Tumor-Agnostic

Neoplasms

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06104449 2026-04-27

MK-5684-005

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT06136598 2026-03-19

MK-5684-001

Merck Sharp & Dohme LLC

Phase 1 Completed
14 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡